What Debridat 200 Treats

Debridat 200, containing the active substance trimebutine maleate, is a medication primarily used to manage functional gastrointestinal disorders. It acts as a musculotropic antispasmodic agent, helping to regulate the motility of the digestive tract.

Main Uses and Indications

The medication is indicated for the treatment of various symptoms associated with the gastrointestinal system, specifically focusing on restoring normal movement in the digestive tract. The main clinical applications include:

• Irritable Bowel Syndrome (IBS): It is frequently used to manage the symptoms of IBS, including abdominal pain, cramping, and discomfort.
• Functional Bowel Disorders: It helps address irregularities in bowel movements, such as constipation or diarrhea, by stabilizing intestinal motility.
• Gastrointestinal Pain: The medication is used to provide relief from localized pain and spasms in the lower digestive tract.
• Post-Operative Ileus: In some clinical settings, it may be used to assist in the recovery of intestinal transit following abdominal surgery.

Benefits and Mechanism of Action

Debridat 200 is characterized by its dual effect on the gut. Unlike many medications that only suppress movement, trimebutine acts as a regulator:

• Normalization of Motility: It can stimulate intestinal activity when it is too slow (prokinetic effect) or inhibit it when it is overactive (antispasmodic effect). This makes it versatile for treating fluctuating bowel patterns.
• Visceral Hypersensitivity Reduction: By modulating peripheral opioid receptors in the gut wall, it helps reduce the sensitivity of the digestive system to stretching and gas, which often causes pain in patients with functional disorders.
• Symptom Management: The primary benefit is the reduction of chronic abdominal discomfort, allowing for an improvement in the patient's daily quality of life without significantly affecting the central nervous system.

Regulatory References

1. Health Canada Product Monograph

Eligibility Map: Who can and cannot use Debridat 200 — Official Regulatory Information

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults are the standard population for approved use. Adolescents (age 12 and above) are considered eligible in certain documents.
Populations for whom use is contraindicated	Patients with known hypersensitivity to trimebutine maleate or any excipients. Children under 2 years of age (in some regional documents). Patients with galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption (for tablet form).
Age-related eligibility rules	Use is contraindicated under 2 years of age in some regions, while other documents state it is not recommended for use in children under 12 years of age.
Pregnancy and lactation eligibility status	Pregnancy (First Trimester): Use is not recommended due to insufficient human data. Lactation: Use is not recommended as safety is not established and passage into breast milk is unknown.
Eligibility-related restrictions	Use during the 2nd and 3rd trimesters of pregnancy is conditional; it should not be considered unless necessary and the benefit outweighs the risk.

---

Eligibility Classifications (High-Level)

Category	Official Regulatory Classification/Wording
Eligibility severity classification	Contraindicated, Not Recommended, Use Should Not Be Considered Unless Necessary (as defined in official documents).

---

Connection to the overall eligibility profile

Official regulatory documents define who can and cannot use the medicine by establishing populations and conditions as either absolutely contraindicated (e.g., hypersensitivity, specific metabolic disorders, young children in some regions) or as groups where use is strictly conditional or not recommended (e.g., pregnancy, lactation, children under 12 years). This framework provides mandatory boundaries for use.

Interactions with other medicines and products

Debridat 200 contains the active substance trimebutine maleate. Official regulatory documents, which govern the safe use of this medicine, indicate a very limited and specific interaction profile.

---

Documented Interactions

Interacting Product	Clinical Effect Noted in Studies
d-tubocurarine	Trimebutine has been shown in animal studies to increase the duration of curarization (neuromuscular blockade) induced by d-tubocurarine. This is a procedural interaction relevant when the drug is used in surgical or critical care settings.

---

General Interaction Profile

Some official labels explicitly state that no other drug interactions have been observed in clinical trials or have been otherwise reported. For example, one regulatory document states “CONTRAINDICATIONS – DRUG INTERACTIONS: None.”

It is important to understand that Trimebutine maleate is not an FDA-approved drug and is not widely available in the United States; its official labeling is primarily based on international health authorities. Patients should always inform their healthcare provider of all medicines, supplements, and herbal products they are taking before starting treatment to manage any potential risks, even if the documented interaction profile is narrow.

Modulation of Nerve Communication (Peripheral Opioid Receptors)

Debridat 200 (Trimebutine) initiates its effect by acting as a modulator on multiple peripheral opioid receptors (mu, kappa, and delta) located on the nerve cells within the enteric nervous system (ENS). This interaction adjusts the release of key neurotransmitters that communicate signals to the smooth muscles. This process contributes to the resulting effect on digestive tract motor function.

---

Direct Regulation of Smooth Muscle Electricity (Ion Channels)

Trimebutine also exerts a direct mechanistic effect on the smooth muscle cells by modulating specific voltage-gated ion channels (such as calcium and potassium). By influencing this ion flux, the drug modifies the muscle cell's electrical charge, which controls the intensity and timing of smooth muscle contractions.

---

Adjustment of Gut Motility Rhythm (Dual Mechanistic Action)

The combined effect of nerve signal modulation and muscle electricity control results in a dual mechanistic action on gut motility. Trimebutine exhibits a concentration-dependent activity, capable of both stimulating and inhibiting smooth muscle contractions. The compound’s activity modulates the Migrating Motor Complex (MMC) cycle by inducing premature phase III activity in the small intestine. This mechanism modifies the pattern of peristalsis, contributing to the adjustment of bowel transit time.

How to Use Debridat 200

The administration of Trimebutine maleate (Debridat 200) follows specific instructions that define the route, dosage limits, and timing relative to food intake. This information is based on established prescribing guidelines.

---

Official Administration Guidelines

Feature	Official Instruction
Route of Administration	The film-coated tablet form is approved for oral administration.
Standard Adult Dose	The maximum total daily dose for adults is typically 600 mg, administered in divided amounts.
Dosing Frequency	The medication is taken three times daily (TID) to ensure consistent delivery of the total dose.
Timing Relative to Meals	Each dose must be taken before meals (pre-prandially), which is a key instruction for proper use.

---

Procedural and Population Rules

Official Step Sequence

The standard procedure is structured around three key actions:

• The 200 mg film-coated tablet is ingested by mouth.
• The administration is timed to occur before a meal.
• This process is repeated to achieve a total of three administrations per day.

Handling a Missed Dose

If the administration of a scheduled dose is forgotten, the guidance is to take the dose as soon as it is remembered. However, if the time is close to the next scheduled dose, the missed dose must be skipped to maintain the correct dosing interval and prevent an accidental doubling of the prescribed amount.

Age-Group Restriction

Official labeling contains a specific age restriction, stating that Trimebutine maleate is not recommended for use in children under 12 years of age.

These instructions define the standardized protocol for using the medicine according to established clinical standards.

Debridat 200: Overview of Clinical Evidence

Research for Trimebutine was studied for use in various conditions characterized by fluctuating or episodic gastrointestinal manifestations. The evidence base includes Randomized Controlled Trials (RCTs) and summaries compiled in meta-analyses that explore outcomes related to physical discomfort and daily functioning.

---

Evidence for Functional Gastrointestinal Conditions

Studies primarily examined the use of Trimebutine for Irritable Bowel Syndrome (IBS). In this context, investigators monitored how symptoms evolved over defined time intervals, tracking changes in abdominal pain and bowel habits. Research also explored its application in Functional Dyspepsia (FD), where studies tracked changes in global symptom severity and objective measures like gastric emptying time. Additionally, Trimebutine was studied for use in acute scenarios involving temporary physiological imbalance, such as supporting the return of normal gut function after abdominal surgery by monitoring the time until the resumption of intestinal movement.

---

Research Limitations and Uncertainty

The available research consists primarily of short-term trials, with follow-up durations that were limited, commonly lasting only a few weeks to two months. Consequently, there is limited information for long-term outcomes, and the sustained nature of recorded symptom changes long-term effects are not fully established. Research explored special population subsets, including elderly patients and pediatric patients. However, data for certain groups, or comparative evidence against all competing established agents, is lacking in some contexts. The overall findings often show heterogeneity across different studies due to variations in trial design.

Key Studies & References

1. Trimebutine Maleate and Pinaverium Bromide for Irritable Bowel Syndrome: A Review of the Clinical Effectiveness, Safety and Guidelines. Rapid Response Report: Summary With Critical Appraisal
2. Trimebutine Maleate Product Monograph (Health Canada)

Common questions about Debridat 200 (FAQ)

Q: How quickly should someone typically expect Debridat 200 to start having an effect?

According to official product information, the active substance in Debridat 200 is rapidly absorbed into the system after it is taken orally. Pharmacokinetic studies indicate that the concentration of the active substance in the blood typically reaches its highest point within approximately one hour after administration. This finding relates to systemic availability, not the onset of symptomatic relief.

Q: Can Debridat 200 be taken at the same time as antacids?

Official labeling for Debridat 200 states that no other drug interactions have been broadly observed or reported in clinical trials, apart from one specific procedural interaction. However, official documents do not contain specific information regarding interactions with common non-prescription medicines, such as antacids.

Q: Does Debridat 200 interact with common over-the-counter painkillers?

Official regulatory documents indicate that the drug has a limited and specific interaction profile. Beyond one noted procedural interaction, no other drug interactions have been broadly observed or reported in studies. Specific interactions with common over-the-counter painkillers are not detailed in the official product information, which indicates a limited interaction profile.

Q: Can people with known liver problems safely use Debridat 200?

Official product information indicates that for patients with hepatic impairment (liver problems), an altered dosage may be required. This is noted because liver function can potentially change how the body processes the medication. Information on this requirement is detailed in the official prescribing documentation.

Q: Does the drug cause any issues with driving or operating machinery?

The official safety profile for Debridat 200 includes adverse effects such as drowsiness and dizziness. Regulatory documents note that these effects may impair a person's ability to drive or operate machinery, and caution is advised regarding this potential hazard.

Q: Can Debridat 200 interact with natural or herbal sleep aids?

Regulatory documents state that the drug has a limited interaction profile. While one specific procedural interaction is documented, no other drug interactions have been broadly observed or reported in studies. Specific interactions with herbal or natural sleep aids are not detailed in the official product information, which indicates a limited interaction profile.

Q: Is it safe to consume caffeine while taking Debridat 200?

Official labeling indicates a specific and limited interaction profile for Debridat 200. Beyond one documented procedural interaction, no other drug interactions have been observed or reported in studies. Specific interactions with food, general beverages, or caffeine are not detailed in the official product information, which indicates a limited interaction profile.

Q: Does Debridat 200 contain lactose or gluten?

The film-coated tablet form of Debridat 200 typically contains lactose as an excipient. Due to this, the medication is contraindicated for individuals with specific hereditary metabolic disorders, such as galactose intolerance. Official labeling usually confirms all excipients, but gluten is not typically listed as a primary excipient concern.

Q: Is it possible for Debridat 200 to interact with blood pressure medication?

Official product information states that no other drug interactions have been observed during clinical trials, besides d-tubocurarine. Specific interactions with common drug classes, such as blood pressure medication, are not detailed in the official product information, which indicates a limited interaction profile.

Q: Is Debridat 200 available without a prescription in some countries?

Official regulatory classification indicates that Debridat 200 is generally classified as a prescription synthetic medicine in its primary international markets. This means that a prescription is typically required for its dispensing. The exact regulatory status is defined by the local health authority in each individual country.

Q: Does using Debridat 200 require any dietary changes?

The official administration instructions require the medication to be taken before meals. Beyond this specific instruction regarding timing, official labeling does not typically dictate or mandate specific dietary changes or restrictions that must be followed while using the medicine.

Q: How does Debridat 200 work differently from other common gut treatments?

Regulatory documents describe the action of Trimebutine as a noncompetitive spasmolytic agent and a motility regulator. Its function is unique because it works through a multimodal action—modulating nerve signals via opioid receptors and controlling muscle electricity via ion channels—which differentiates it from simple, single-mechanism gut treatments.

Q: Does Debridat 200 have an effect on mental clarity or mood?

The official safety profile includes nervous system adverse effects such as drowsiness, fatigue, dizziness, and headache. While these may affect mental clarity, there is no explicit mention of specific adverse effects related to mood (such as anxiety or depression) listed in the adverse reaction categories.

Q: Can older adults use Debridat 200 without special precautions?

While older adults are an eligible population, official documents sometimes suggest that special consideration regarding the amount administered may need to be applied for geriatric patients. This is to account for potential differences in drug processing.

Q: What is the difference between Debridat 100 and Debridat 200?

The numerical designation on the product packaging indicates the strength of the tablet. Debridat 200 contains 200 mg of the active ingredient, Trimebutine, which is exactly double the strength of the 100 mg formulation.

Q: What is the risk profile of Debridat 200 compared to placebo in clinical studies?

Clinical trial results often show that adverse effects associated with the drug are typically of low to moderate severity and are reported in only a small percentage of patients. The official clinical trial summaries document the specific incidence rates of adverse events in comparison to the placebo group.

Q: Why might a doctor prescribe Debridat 200 instead of a different gastrointestinal treatment?

The drug is prescribed for functional gastrointestinal conditions, such as Irritable Bowel Syndrome (IBS). It is valued for its unique dual action as a motility regulator that has the functional ability to both stimulate sluggish movement and calm excessive, spastic contractions, addressing a specific need in gut function.

Q: Is it normal to experience temporary stomach upset when first starting Debridat 200?

The official adverse reaction list includes common gastrointestinal issues such as nausea, constipation, diarrhea, and dyspepsia. These effects are reported and can occur when starting treatment.

How to Store and Dispose of Debridat (Trimebutine Maleate)

The official requirements for storing and disposing of Debridat film-coated tablets are defined by regulatory labeling to ensure product stability and public safety.

---

Official Storage Conditions

• Temperature Constraint: The medicine must be stored at a temperature that is below 30°C.
• Product Integrity: It is essential not to use this medicine after the expiry date ("EXP") shown on the blister or carton.
• Child Safety: For safety, the product must always be kept out of the sight and reach of children.

---

Disposal Requirements

• Environmental Restriction: Do not dispose of unused or expired tablets by throwing them away via wastewater or general household waste.
• Official Procedure: To properly discard the medicine, you must ask a pharmacist for guidance on disposal, as these measures help to protect the environment.